Moleculin Biotech, Inc. MBRX
8.10 USD +0.09 (+1.12%)
At closeNov 12, 2026, 4:21 AM EST
8.34 +0.24 +2.94%
Pre-market · Nov 12, 4:21 AM ET
8.00 Day range 8.40
3.22 52-week range 253.00
- YTD
- +144.71%
- 1 year
- -32.39%
News
benzinga.com Moleculin Biotech Reports Preclinical Data Showing Annamycin Plus PD-1 Blockade Extends Survival in Pancreatic Cancer Models Inhibition of CD8+ T cells shortens survival in Annamycin-treated mice, demonstrating the immune system is a functional contributor to Annamycin’s antitumor activity, not a bystanderAnnamycin…
globenewswire.com Preclinical Data Show Annamycin Makes Pancreatic Cancer Responsive to Checkpoint Inhibitors, Opening a Combination Path with Immunotherapies Inhibition of CD8+ T cells shortens survival in Annamycin-treated mice, demonstrating the immune system is a functional contributor to Annamycin's antitumor activity, not a bystander
benzinga.com Moleculin Reports 43% And 36% Complete Remission Rates In Annamycin Phase 2/3 Trial For Relapsed Or Refractory AML First interim results from pivotal Phase 2/3 trial highlight encouraging remission rates in patients with relapsed or refractory AMLMoleculin Biotech, Inc. (NASDAQ:MBRX) ("Moleculin" or the "Company")- benzinga.com Moleculin Biotech Completes Participant Dosing In Part A Of Its Pivotal Phase 2/3 MIRACLE Study Of Annamycin To Treat Adults With Relapsed Or Refractory Acute Myeloid Leukemia Moleculin Biotech, Inc. (Nasdaq: MBRX) ("Moleculin" or the "Company") today announced that dosing has been completed in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares rose 23.1% to $89.86 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 billion. As per the press release,…
benzinga.com Moleculin Biotech Announces 1-For-20 Reverse Stock Split, Effective October 20 Filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split of its common stock. The…